Form 8-K - Current report:
SEC Accession No. 0001104659-25-020313
Filing Date
2025-03-04
Accepted
2025-03-04 16:14:50
Documents
14
Period of Report
2025-03-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm258144d1_8k.htm   iXBRL 8-K 25765
2 EXHIBIT 99.1 tm258144d1_ex99-1.htm EX-99.1 98365
  Complete submission text file 0001104659-25-020313.txt   314611

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rigl-20250304.xsd EX-101.SCH 3006
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rigl-20250304_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rigl-20250304_pre.xml EX-101.PRE 22353
16 EXTRACTED XBRL INSTANCE DOCUMENT tm258144d1_8k_htm.xml XML 3699
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29889 | Film No.: 25704570
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)